NCT04648475

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Status unknown Phase 1, PHASE2 Last updated 18 April 2023

What this trial tests

Phase 1, PHASE2 trial testing CD19 and CD22 targeted CAR-T cells in Leukemia, B-cell in 40 participants. Status unknown.

Timeline

25 August 2020

Primary endpoint
31 December 2023

1 July 2024

Quick facts

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	25 August 2020
Primary completion	31 December 2023
Estimated completion	1 July 2024
Sites	1 location across China

Drugs / interventions tested

• CD19 and CD22 targeted CAR-T cells — full drug profile →

Conditions studied

• Leukemia, B-cell — all drugs for Leukemia, B-cell →
• Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →

Sponsor

Chongqing Precision Biotech Co., Ltd — full company profile →

Who can join

Adults 3 to 75, any sex, with Leukemia, B-cell or Lymphoma, B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
   Razeghian E, Nasution MKM, Rahman HS, Gardanova ZR, et al · · 2021 · cited 80× · PMID 34321099 · DOI 10.1186/s13287-021-02510-7
2. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.
   Ai K, Liu B, Chen X, Huang C, et al · · 2024 · cited 49× · PMID 39501358 · DOI 10.1186/s13045-024-01625-7
3. Targeting CD22 for the Treatment of B-Cell Malignancies.
   Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546
4. CRISPR, CAR-T, and NK: Current applications and future perspectives.
   Khoshandam M, Soltaninejad H, Hamidieh AA, Hosseinkhani S. · · 2024 · cited 11× · PMID 38545126 · DOI 10.1016/j.gendis.2023.101121
5. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.
   Atrash S, Moyo TK. · · 2021 · cited 11× · PMID 33814917 · DOI 10.2147/ott.s242018
6. CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
   Ostojska M, Nowak E, Twardowska J, Lejman M, et al · · 2023 · cited 5× · PMID 38003910 · DOI 10.3390/jpm13111595